Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Muscular Dystrophies Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

8 recruiting trials for Muscular Dystrophies. Eligibility criteria explained in plain English.

TrialFinderData lists 8 Muscular Dystrophies clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 3 is the largest group at 50% (1 studies); the largest phase groups are Phase 3: 1, Phase 2: 1.

Research is led by Leigh R. Hochberg, MD, PhD. (2), Karunesh Ganguly (1), Johns Hopkins University (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is BrainGate Neural Interface System (device, 2 trials), followed by Placebo, PMT/Blackrock Combination Device.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
8
Total Trials
8
Recruiting Now
1
Phase 3 Trials
7
Sponsors

Track Muscular Dystrophies trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT05724173

Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia

The purpose of this study is to obtain preliminary device safety information and demonstrate proof of principle (feasibility) of the ability of people with tetraplegia to control...

Sponsor: Leigh R. Hochberg, MD, PhD.Enrolling: 32 locations
RECRUITINGNCT03698149

ECoG BMI for Motor and Speech Control

Test the feasibility of using electrocorticography (ECoG) signals to control complex devices for motor and speech control in adults severely affected by neurological disorders.

Sponsor: Karunesh GangulyEnrolling: 31 location
RECRUITINGNCT06094205

Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Speech-02)

The goal of this study is to improve our understanding of speech production, and to translate this into medical devices called intracortical brain-computer interfaces (iBCIs) that...

Sponsor: Leigh R. Hochberg, MD, PhD.Enrolling: 21 location
RECRUITINGNCT07521930

Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT)

The goal of this clinical trial is to evaluate the safety and preliminary efficacy of an implantable device that records and stimulates different areas of the brain to allow...

Sponsor: Johns Hopkins UniversityEnrolling: 51 location
RECRUITINGPhase 3NCT07608432

Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in...

The purpose of the study is to assess the efficacy, safety, and tolerability of zeleciment rostudirsen (DYNE-251) administered intravenously (IV) every 4 weeks to ambulatory...

Sponsor: Dyne TherapeuticsEnrolling: 901 location
RECRUITINGNCT07129954

Fear of Falling in Muscular Dystrophy

Primary objectives WP1: Evaluate the prevalence of FOF in the study population and how this varies over time. Evaluate whether there are relationships between the variables...

Sponsor: Universita di VeronaEnrolling: 1001 location
RECRUITINGPhase 2NCT07287189

Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients

Phase 2a trial of SAT-3247 in ambulatory DMD patients aged ≥ 7 and \< 10 years. The trial will study two doses of SAT-3247 in a randomized, double-blind, placebo-controlled...

Sponsor: Satellos Bioscience, Inc.Enrolling: 5120 locations
RECRUITINGNCT06666816

Observational Study to Observe Variations of Gait Parameters in Patients With Neuromuscular Diseases

This study has the general objective of observing walking parameters during a clinical test to objectively estimate fatigue in patients with neuromuscular diseases. Furthermore,...

Sponsor: IRCCS Eugenio MedeaEnrolling: 1202 locations

Frequently Asked Questions

There are currently 8 clinical trials for Muscular Dystrophies, with 8 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Muscular Dystrophies, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 1 Phase 3 trials for Muscular Dystrophies, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.